Adding Zoledronic Acid to Endocrine Therapy for Premenopausal Breast Cancer

European trial results suggest that adding IV bisphosphonate therapy improves outcomes.

Results of a 2008 industry-funded Austrian trial showed that intravenous administration of the bisphosphonate, zoledronic acid (ZA; Reclast), prevented bone-density loss in premenopausal women with receptor-positive breast cancer who received ovarian-suppression therapy (JW Womens Health Sep 25 2008). In a substudy, investigators have assessed ZA’s effect on cancer-related outcomes. Eligible participants were premenopausal; had undergone primary surgery for stage I or II breast cancer that was estrogen-receptor positive, progesterone-receptor positive, or both; and were scheduled to initiate ovarian-suppression therapy with the gonadotropin-releasing hormone agonist goserelin (Zoladex). Women received postoperative radiation therapy but not…

Reviewing Author

Andrew M. Kaunitz, MD

Disclosures

RoyaltiesUpToDate

Grant/Research SupportMerck, Mithra, Medicines360

Editorial BoardsContraception; Menopause; Contraceptive Technology Update; OBG Management; Medscape OB/GYN & Women’s Health

Andrew M. Kaunitz, MD

Disclosures

RoyaltiesUpToDate

Grant/Research SupportMerck, Mithra, Medicines360

Editorial BoardsContraception; Menopause; Contraceptive Technology Update; OBG Management; Medscape OB/GYN & Women’s Health

Adding Zoledronic Acid to Endocrine Therapy for Premenopausal Breast Cancer

Topics

Reviewing Author